← Eichor
Study identifier: NCT05976685 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy

Condition: Ischemic Stroke · Atrial Fibrillation  ·  Sponsor: Insel Gruppe AG, University Hospital Bern

PhaseNA
Planned participants482
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF. Despite DOAC therapy, there is a significant residual stroke risk of 1-2%/year. Recent data from the Swiss Stroke Registry found 38% of patients with AF and ischemic stroke were on prior anticoagulant therapy (approximately 400 patients per year in Switzerland). The investigators found in a prior observational study, that patients with AF who have ischemic stroke despite anticoagulation are at increased risk of having another ischemic stroke (HR 1.6; 95% confidence interval, CI 1.1-2.1). Combining observational data from 11 international stroke centres, the investigators found that the majority of ischemic strokes despite anticoagulation in patients with AF is "breakthrough" cardioembolism (76% of patients) and only a minority of 24% is related to other causes unrelated to AF. Optimal secondary prevention strategy is unknown. The investigators have conducted two independent observational studies including together \>4000 patients but did not identify any strategy (e.g. switch to different DOAC, additional antiplatelet therapy) that seems superior. A recent randomized controlled trial on surgical occlusion of the left atrial appendage (LAAO) found that LAAO may provide additional protection from ischaemic stroke in addition to oral anticoagulation. Triggered …

This description comes directly from the study's public registry record.

Talk to the study team

Lorenz Räber, Prof., MD, PhD  ·  +41316320929  ·  Lorenz.Raeber@insel.ch

David Seiffge, Prof., MD  ·  +41316640509  ·  david.seiffge@insel.ch

Always discuss trial participation with your own doctor first.

Locations (30)

UCLouvain - Cliniques universitaires Saint-LucBrussels, Brussels Capital, BelgiumRecruiting
AZ Sint Jan BruggeBruges, BelgiumRecruiting
Brussels University HospitalBrussels, BelgiumRecruiting
HUmani CHU Charleroi-ChimayCharleroi, BelgiumRecruiting
Universitair Ziekenhuis (UZ) LeuvenLeuven, BelgiumRecruiting
CHU Liège Sart-TilmanLiège, BelgiumRecruiting
Asklepios Klinik AltonaHamburg, Free and Hanseatic City of Hamburg, GermanyRecruiting
Universitätsklinikum LeipzigLeipzig, Leipzig, GermanyRecruiting
Universitätsmedizin MannheimMannheim, Mannheim, GermanyRecruiting
UKSH, Campus LübeckLübeck, Schleswig-Holstein, GermanyRecruiting
Charité-Universitätsmedizin BerlinBerlin, State of Berlin, GermanyRecruiting
Universitätsklinikum BonnBonn, GermanyRecruiting

+ 18 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05976685